2011
conference-abstract
OpenAlex
Henrik Illum, Syed Hasan Raza Jafri, J. Mclarty, Glenn Morris Mills et autres
e18050 Background: E is an oral tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). Polyphenon E is a green tea extract containing mainly epigallocatechin gallate (EGCG) which inhibits c-met and vascular endothelial growth factor (VEGF) signaling. In vitro …
2010
conference-abstract
OpenAlex
Karen L. Reckamp, Mariana Koczywas, Mihaela C. Cristea, Jeanette M. Dowell et autres
TPS337 Background: Signaling through the cyclooxygenase-2 (COX-2) pathway presents a novel mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC). This resistance is mediated through an EGFR-independent activation of MAPK/Erk by …
2010
conference-abstract
OpenAlex
Drew Warren Rasco, Jinyin Yan, Jeanette M. Dowell, David E. Gerber
e18006 Background: Despite evidence that chemotherapy prolongs survival, without substantially impairing quality of life, for patients with advanced non-small cell lung cancer (NSCLC), population-based studies have shown that only 20-30% of these patients receive systemic therapy. However, these studies have relied on …
2010
conference-abstract
OpenAlex
Sofyan M. Radaideh, Deanna Gerber, Frank Dunphy, Junjie Yan et autres
e18012 Background: B is a monoclonal antibody targeting VEGF with demonstrated efficacy in several solid tumors. HTN is a common toxicity of VEGF-targeted therapies, including B, and is a potential surrogate marker of activity for these agents. Methods: We performed a retrospective …
Accès ouvert
2008
article
OpenAlex
David A. Reardon, Michael R. Zalutsky, Gamal Akabani, R. Edward Coleman et autres
The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a patient-specific, …
us
(code pays fourni par la source)
2005
article
OpenAlex
David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman et autres
PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients. PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created …
us
(code pays fourni par la source)
2005
article
OpenAlex
David Alan Rizzieri, Liang Piu Koh, Gwynn Douglas Long, Cristina Gasparetto et autres
Abstract We have investigated the use of partially matched family member donors in combination with alemtuzumab and a non-myeloablatvie preparative regimen in an effort to expand the population of patients who may benefit from allogeneic immunotherapy. Methods: Sixty three patients received fludarabine …
us
(code pays fourni par la source)
2004
conference-abstract
OpenAlex
Monica M. Bertagnolli, Mark S. Redston, B. Miedema, Jeanette M. Dowell et autres
3506 The most important outcome predictor for resectable colon cancer (RCC) is the status of locoregional lymph nodes. This information is critical, as patients with positive nodes may benefit from post-operative adjuvant therapy. A subset of patients with node-negative RCC experiences a …
us, ca
(code pays fourni par la source)
2004
conference-abstract
OpenAlex
Monica M. Bertagnolli, Mark S. Redston, B. Miedema, Jeanette M. Dowell et autres
3506 The most important outcome predictor for resectable colon cancer (RCC) is the status of locoregional lymph nodes. This information is critical, as patients with positive nodes may benefit from post-operative adjuvant therapy. A subset of patients with node-negative RCC experiences a …
us, ca
(code pays fourni par la source)